Formulary Oversight For Obamacare Plans Will Be Deferred In Some States
Executive Summary
Patient groups raise concerns that states may not be able to monitor formularies for discrimination, limiting patient access to drug coverage.
You may also be interested in...
HIV Drug Copay Case Spotlights Discriminatory Formulary Issue In Exchange Plans
Cigna agrees to cap cost-sharing for some HIV/AIDS drugs at $200 in its exchange plans in Florida as a result of a consent agreement with state regulators. AIDS activists had filed a complaint with HHS alleging Cigna and three other insurers in the state were discriminating against patients with their high copays for HIV/AIDS drugs.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.